Clinical trial · Interventional
Pan Tumor Rollover Study
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
NCT03899155CI-TRIAL-00119695recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (19)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Cabozantinib | Drug | Cabozantinib | ALIAS |
| Capecitabine | Drug | Capecitabine | ALIAS |
| Daratumumab | Drug | Daratumumab | ALIAS |
| Enzalutamide | Drug | Enzalutamide | ALIAS |
| Fluorouracil | Drug | Fluorouracil | ALIAS |
| Ipilimumab | Drug | Ipilimumab | ALIAS |
| Leucovorin | Drug | Leucovorin | ALIAS |
Design
Arms and outcomes
Arms (32)
- type
- EXPERIMENTAL
- label
- A1: Nivolumab Monotherapy Dose 1
- interventionNames
- Drug: Nivolumab
- type
- EXPERIMENTAL
- label
- A2: Nivolumab Monotherapy Dose 2
- interventionNames
- Drug: Nivolumab
- type
- EXPERIMENTAL
- label
- B1: Nivolumab + Ipilimumab
- interventionNames
- Drug: Nivolumab
- Drug: Ipilimumab
- type
- EXPERIMENTAL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Signed Written Informed Consent. * Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study. * On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study. * WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF. Exclusion Criteria * Participant is not eligible for study treatment per the Parent Study eligibility criteria. * Participants not receiving clinical benefit as assessed by the Investigator. * Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant. * Other protocol-defined Inclusion/Exclusion Criteria apply
References
Publications (0)
Data not yet available
No reference posted for this study.